Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909

Journal of Clinical Oncology

Volumn 27, Issue 36, 2009, Pages 6101-6108

  Damon, Lloyd E ^a   Johnson, Jeffrey L ^a   Niedzwiecki, Donna ^a   Cheson, Bruce D ^a   Hurd, David D ^a   Bartlett, Nancy L ^a   LaCasce, Ann S ^a   Blum, Kristie A ^a   Byrd, John C ^a   Kelly, Michael ^a   Stock, Wendy ^a   Linker, Charles A ^a   Canellos, George P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CARMUSTINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUCONAZOLE; FOLINIC ACID; LEVOFLOXACIN; METHOTREXATE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CENTRAL NERVOUS SYSTEM DISEASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HUMAN; INFECTION; LEUKAPHERESIS; LIVER DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; METABOLIC DISORDER; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN DISEASE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; SURVIVAL RATE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTARABINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; FEMALE; FILGRASTIM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; PREDNISONE; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; VINCRISTINE;

EID: 74949115388     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.2554     Document Type: Article

References (45)

1. Witzig TE: Current treatment approaches for mantle-cell lymphoma. J Clin Oncol 23:6409-6414, 2005
2. Brody J, Advani R: Treatment of mantle cell lymphoma: Current approach and future directions. Crit Rev Oncol Hematol 58:257-265, 2006
3. Andersen NS, Jensen MK, de Nully Brown P, et al: A Danish population-based analysis of 105 mantle cell lymphoma patients: Incidences, clinical features, response, and prognostic factors. Eur J Cancer 38:401-408, 2002
4. Fernández V, Hartmann E, Ott G, et al: Pathogenesis of mantle-cell lymphoma: All oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 23:6364-6369, 2005
5. Bertoni F, Rinaldi A, Zucca E, et al: Update on the molecular biology of mantle cell lymphoma. Hematol Oncol 24:22-27, 2006
6. Benn HAN: Mantle cell lymphoma and other t(11;14)-related disorders: From biology to designing therapy. Mol Oncol Rep 1:42-48, 2006
7. Lenz G, Dreyling M, Hoster E, et al: Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23:1984-1992, 2005
8. Zelenetz AD: Mantle cell lymphoma: An update on management. Ann Oncol 17:iv12-iv14, 2006
9. McLaughlin P, Grillo-López AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
10. Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927-1932, 1998
11. Foran JM, Rohatiner AZ, Cunnigham D, et al: European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and small B-cell lymphocytic lymphoma. J Clin Oncol 18:317-324, 2000
12. Ghielmini M, Schmitz SF, Bürki K, et al: The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 11:123-126, 2000
13. Romaguera JE, Fayad L, Rodriguez MA, et al: High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cyatarabine. J Clin Oncol 23:7013-7023, 2005
14. Khouri IF, Romaguera J, Kantarjian H, et al: Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 16:3803-3809, 1998
15. Vandenberghe E, Ruiz de Elvira C, Loberiza FR, et al: Outcome of autologous transplantation for mantle cell lymphoma: A study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 120:793-800, 2003
16. Hicks L, Connors JM, Mangel J, et al: Autologous stem-cell transplant with a rituximab purge and maintenance vs. standard chemotherapy for mantle cell lymphoma: Extended follow-up of a matched pair analysis. Blood 108:868a, 2006 (abstr 3051)
17. Cortelazzo S, Magni M, Pintimalli M, et al: Frontline high dose sequential chemotherapy with rituximab (R-HDS) and autologous stem cell transplantation induces high rates of complete response and prolongs survival in mantle cell lymphoma (MCL). Blood 108:866a, 2006 (abstr 3045)
18. Vose J, Loberiza F, Bierman P, et al: Mantle cell lymphoma (MCL): Induction therapy with HyperCVAD/High-dose methotrexate and cytarabine (M-C) (±rituximab) improves results of autologous stem cell transplant in first remission. J Clin Oncol 24:424s, 2006 (abstr 7511)
19. Van't Veer MB, Notenboom A, McKenzie M, et al: First report of NOVON 45: A phase II study with rituximab, high dose Ara-C and autologous stem cell transplantation in the primary treatment of mantle cell lymphoma. Blood 108:773a, 2006 (abstr 2734)
20. Dreyling M, Lenz G, Hoster E, et al: Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progressionfree survival in mantle cell lymphoma: Results of a prospective randomized trial of the European MCL Network. Blood 105:2677-2684, 2005
21. Dreyling MH, Hoster E, Van Hoof A, et al: Early consolidation with myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission in mantle cell lymphoma: Long term follow up of a randomized trial. Blood 112:285a, 2008 (abstr 769)
22. Soussain C, Patte C, Ostronoff M, et al: Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with LMB pediatric protocols. Blood 85:664-674, 1995
23. Damon L, Damon LE, Gaensler K, et al: Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma. Bone Marrow Transplant 42:649-657, 2008
24. Flinn IW, O'Donnell PV, Goodrich A, et al: Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 6:628-632, 2000
25. Arcaini L, Orlandi E, Alessandrino EP, et al: A model of in vivo purging with Rituximab and highdose Ara-C in follicular and mantle cell lymphoma. Bone Marrow Transplant 34:175-179, 2004
26. Horwitz SM, Negrin RS, Blume KG, et al: Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 103:777-783, 2004
27. Majlis A, Pugh W, Rodriguez M, et al: Mantle cell lymphoma: Correlation of clinical outcome and biologic features with three different histologic variants. J Clin Oncol 15:1664-1671, 1997
28. Linker CA, Ries CA, Damon LE, et al: Autologous stem cell transplantation for acute myeloid leukemia in first remission. Biol Blood Marrow Transplant 6:50-57, 2000
29. Smith GA, Damon LE, Rugo HS, et al: Highdose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol 15:833-839, 1997
30. Stockerl-Goldstein KE, Horning SJ, Negrin RS, et al: Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2:76-85, 1996
31. Cao TM, Negrin RS, Stockerl-Goldstein KE, et al: Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 6:387-394, 2000
32. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244, 1999
33. Cancer Therapy Evaluation Program, Common Terminology for Adverse Events, version 3.0. March 31, 2003. http://ctep.cancer.gov
34. Hoster E, Dreyling M, Klapper W, et al: A new prognostic index (MIPI) for patients with advancedstage mantle cell lymphoma. Blood 111:558-565, 2008
35. Altman DG, Gore SM, Gardner MJ, et al: Statistical guidelines for contributors to medical journals. BMJ 286:1489-1493, 1983
36. Khouri IF: Reduced-intensity regimens in allogeneic stem-cell transplantation for non-hodgkin lymphoma and chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2006:390-397
37. Romaguera J, Fayad L, Rodriguez A, et al: Rituximab + hyperCVAD alternating with R-methotrexate/ cytarabine after 9 years: Continued high rate of failurefree survival in untreated mantle cell lymphoma. Blood 112:309a, 2008 (abstr 833)
38. Epner EM, Unger J, Miller T, et al: A multi center trial of hyperCVAD+Rituxan in patients with newly diagnosed mantle cell lymphoma. Blood 110: 121a, 2007 (abstr 387)
39. Kahl BS, Longo WL, Eickhoff JC, et al: Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: A pilot study from the Wisconsin Oncology Network. Ann Oncol 17:1418-1423, 2006
40. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
41. Delarue R, Haioun C, Ribrag V, et al: RCHOP and RDHAP followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): Final results of a phase II study from the GELA. Blood 112:218a, 2008 (abstr 581)
42. Cortelazzo S, Magni M, Tarella C, et al: Update of a GITIL cohort study: Frontline high dose sequential chemotherapy with rituximab and autologous stem cell transplantation induces a high rate of long-term remissions in patients with mantle cell lymphoma. Blood 110:386a, 2007 (abstr 1282)
43. Geisler CH, Kolstad A, Laurell A, et al: Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: A nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112:2687-2693, 2008
44. Sher D, Johnson J, Siddiqui M, et al: Eradication of minimal residual disease during treatment of mantle cell lymphoma: CALGB 59909. Blood 104: 459a, 2004 (abstr 1652)
45. Fisher RI, Bernstein SH, Kahl BS, et al: Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24:4867-4874, 2006